Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Change in Cash (2020 - 2025)

Historic Change in Cash for Oncology Institute (TOI) over the last 6 years, with Q3 2025 value amounting to -$2.6 million.

  • Oncology Institute's Change in Cash fell 12399.34% to -$2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$19.7 million, marking a year-over-year decrease of 19938.09%. This contributed to the annual value of $16.2 million for FY2024, which is 1692.68% down from last year.
  • According to the latest figures from Q3 2025, Oncology Institute's Change in Cash is -$2.6 million, which was down 12399.34% from -$9.4 million recorded in Q2 2025.
  • Oncology Institute's Change in Cash's 5-year high stood at $103.6 million during Q4 2021, with a 5-year trough of -$47.4 million in Q4 2022.
  • Over the past 5 years, Oncology Institute's median Change in Cash value was -$1.4 million (recorded in 2023), while the average stood at $1.1 million.
  • Examining YoY changes over the last 5 years, Oncology Institute's Change in Cash showed a top increase of 391957.94% in 2021 and a maximum decrease of 337901.78% in 2021.
  • Oncology Institute's Change in Cash (Quarter) stood at $103.6 million in 2021, then plummeted by 145.75% to -$47.4 million in 2022, then surged by 112.56% to $6.0 million in 2023, then crashed by 61.92% to $2.3 million in 2024, then tumbled by 216.19% to -$2.6 million in 2025.
  • Its last three reported values are -$2.6 million in Q3 2025, -$9.4 million for Q2 2025, and -$9.9 million during Q1 2025.